Gastrointestinal tolerability of once-weekly semaglutide [amount hidden] in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

What Was Tested

This randomized controlled trial paper looks at Semaglutide in the context of fat loss, obesity & body recomposition.

Who Took Part

According to the abstract, 4 adults were involved.

The age groups tagged for this paper are adults.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

WL was analysed by presence/absence of GI AEs.

Mediation analysis estimated WL effects mediated by and unrelated to GI AEs.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity, Overweight, Weight Loss and Semaglutide.

Author keywords: GLP-1 analogue, antiobesity drug, obesity therapy, phase III study, randomized trial and weight control.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 4 adults in people with fat loss, obesity & body recomposition.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.